Interleukin-10 responses to therapeutic vaccination during highly active antiretroviral therapy and after analytical therapy interruption.

Interleukin-10 responses to therapeutic vaccination during highly active antiretroviral therapy and after analytical therapy interruption.

We investigated whether therapeutic vaccination in highly active antiretroviral therapy (HAART)-treated patients with a modified vaccinia virus Ankara-vectored HIV-1 vaccine, with or without therapy interruption, induced the production of interleukin (IL)-10. Plasma IL-10 levels were not significant...

Full description

Bibliographic Details
Main Authors:	Yang, H, Guimarães-Walker, A, Hibbs, S, Dong, T, Stacey, A, Borrow, P, Hanke, T, Davenport, M, McMichael, A, Dorrell, L
Format:	Journal article
Language:	English
Published:	2009

Similar Items

Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences.
by: Touloumi, G, et al.
Published: (2006)

Interruption of antiretroviral therapy is associated with increased plasma cystatin C.
by: Mocroft, A, et al.
Published: (2009)

Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine.
by: Dorrell, L, et al.
Published: (2005)

TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals.
by: Angus, B, et al.
Published: (2008)

Virological remission after antiretroviral therapy interruption in female African HIV seroconverters
by: Gossez, M, et al.
Published: (2018)

Broad TCR usage in functional HIV-1-specific CD8+ T cell expansions driven by vaccination during highly active antiretroviral therapy.
by: Yang, H, et al.
Published: (2007)

Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption
by: Gondim, MVP, et al.
Published: (2021)

Hypophosphataemia with non-tenofovir-containing antiretroviral therapy.
by: Wainwright, E, et al.
Published: (2013)

Thymic Output and CD4 T-Cell Reconstitution in HIV-Infected Children on Early and Interrupted Antiretroviral Treatment: Evidence from the Children with HIV Early Antiretroviral Therapy Trial
by: Lewis, J, et al.
Published: (2017)

Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward.
by: Abbas, U, et al.
Published: (2002)

Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: The role of interleukin 7 and interleukin 7 receptor alpha and microbial translocatioa
by: Rajasuriar, R., et al.
Published: (2010)

Monitoring of highly active antiretroviral therapy in HIV infection.
by: Walker, A, et al.
Published: (2011)

Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection.
by: Gibb, D, et al.
Published: (2004)

Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies
by: Gunst, JD, et al.
Published: (2025)

Enhanced prophylaxis with antiretroviral therapy for advanced HIV in Africa
by: Hakim, J, et al.
Published: (2017)

Response to combination antiretroviral therapy: variation by age.
by: Sabin, C, et al.
Published: (2008)

Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects
by: Hancock, G, et al.
Published: (2017)

Assessment of second-line antiretroviral regimens for HIV therapy in Africa
by: Paton, N, et al.
Published: (2014)

Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy.
by: Dorrell, L, et al.
Published: (2007)

How soon after HIV seroconversion is antiretroviral therapy initiated?
by: Babiker, A, et al.
Published: (1999)

Management of antiretroviral therapy for HIV infection : analyzing when to change therapy
Published: (2003)

Antiretroviral therapy in Malaysia: identifying barriers to universal access
by: Kamarulzaman, A.
Published: (2009)

Universal voluntary HIV testing and immediate antiretroviral therapy.
by: Jaffe, H, et al.
Published: (2009)

Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial
by: Fidler, S, et al.
Published: (2020)

Therapeutic HPV vaccines
by: Hancock, G, et al.
Published: (2017)

Assessment of second-line antiretroviral regimens for HIV therapy in Africa.
by: Paton, N, et al.
Published: (2014)

Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy.
by: Gay, C, et al.
Published: (2011)

Short-course antiretroviral therapy in primary HIV infection.
by: Fidler, S, et al.
Published: (2013)

The effect of antiretroviral therapy on genes involved with mitochondrial function
by: Boothby, M, et al.
Published: (2007)

Pubertal development in HIV-infected African children on first-line antiretroviral therapy.
by: Szubert, A, et al.
Published: (2015)

Predicting the need for third-line antiretroviral therapy by identifying patients at high risk for failing second-line antiretroviral therapy in South Africa
by: Onoya, D, et al.
Published: (2017)

Determinants of antiretroviral therapy coverage in Sub-Saharan Africa
by: Furuoka, Fumitaka, et al.
Published: (2015)

Determinants of antiretroviral therapy coverage in Sub-Saharan Africa
by: Fumitaka Furuoka, et al.
Published: (2015)

HIV-1 protease as a target for antiretroviral therapy
by: Windsor, Ian William.
Published: (2019)

The moral and fiscal implications of antiretroviral therapies for HIV in Africa
by: Collier, P, et al.
Published: (2018)

When to start antiretroviral therapy in HIV-associated tuberculosis.
by: Török, M, et al.
Published: (2011)

Active cytomegalovirus retinitis after the start of antiretroviral therapy
by: Heiden, D, et al.
Published: (2018)

The effect of antiretroviral therapy on genes involved with glucose and lipid metabolism
by: Boothby, M, et al.
Published: (2007)

Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy.
by: Marin, B, et al.
Published: (2009)

Approaches towards avoiding lifelong antiretroviral therapy in paediatric HIV infection.
by: Goulder, P, et al.
Published: (2011)